Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
9 stopped studies mapped to Pancreatic Neuroendocrine Carcinoma and descendants · 56% state a reason
Over the 9 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory… | Phase 2 | terminated | Nov 9, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver… | Phase 2 | terminated | Jan 9, 2014 | ECOG-ACRIN Cancer Research Group | Slow accrual | Enrollment / accrual |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | Phase 2 | terminated | Feb 3, 2017 | H. Lee Moffitt Cancer Center and Research Institute | Slow accrual | Enrollment / accrual |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | Phase 2 | withdrawn | Apr 9, 2014 | Academic and Community Cancer Research United | not stated | Not stated |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic… | Phase 2 | terminated | Oct 24, 2014 | Emory University | Slow accrual | Enrollment / accrual |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | Phase 2 | withdrawn | Sep 28, 2005 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic… | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00428597 | A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell… | Phase 3 | terminated | Jan 30, 2007 | Pfizer | Refer to Detailed Description. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jan 30, 2025source: clinicaltrials